TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects
Open accessThe DOI matches its Crossref record; 221 of the 221 references it cites were found in a registry or an index.
Abstract
Tumor necrosis factor (TNF) is the prototypic pro-inflammatory cytokine. It is central to host defense and inflammatory responses but under certain circumstances also triggers cell death and tissue degeneration. Its pleiotropic effects often lead to opposing outcomes during the development of immune-mediated diseases, particularly those affecting the central nervous system (CNS). The reported contradictions may result from lack of precision in discussing TNF. TNF signaling comprises at minimum a two-ligand (soluble and transmembrane TNF) and two-receptor (TNFR1 and TNFR2) system, with ligands and receptors both differentially expressed and regulated on different cell types. The "functional multiplicity" this engenders is the focus of much research, but there is still no general consensus on functional outcomes of TNF signaling in general, let alone in the CNS. In this review, evidence showing the effects of TNF in the CNS under physiological and pathophysiological conditions is placed in the context of major advances in understanding of the cellular and molecular mechanisms that govern TNF function in general. Thus the roles of TNF signaling in the CNS shift from the conventional dichotomy of beneficial and deleterious, that mainly explain effects under pathological conditions, to incorporate a growing number of "essential" and "desirable" roles for TNF and its main cellular source in the CNS, microglia, under physiological conditions including regulation of neuronal activity and maintenance of myelin. An improved holistic view of TNF function in the CNS might better reconcile the expansive experimental data with stark clinical evidence that reduced functioning of TNF and its dominant pro-inflammatory receptor, TNFR1, are risk factors for the development of multiple sclerosis. It will also facilitate the safe translation of basic research findings from animal models to humans and propel the development of more selective anti-TNF therapies aimed at selectively inhibiting deleterious effects of this cytokine while maintaining its essential and desirable ones, in the periphery and the CNS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–221 of 221
TNF receptor 2 protects oligodendrocyte progenitor cells against oxidative stress
Maier, O., Fischer, R., Agresti, C., & Pfizenmaier, K. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.09.083 · Cited by 64
Mogi, M., Togari, A., Tanaka, K.-I., Ogawa, N., Ichinose, H., & Nagatsu, T. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01275-1 · Cited by 63
Gimenez, M. A. T., Sim, J. E., Archambault, A. S., Klein, R. S., & Russell, J. H. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.050332 · Cited by 63
Differential Oligodendroglial Expression of the Tumor Necrosis Factor Receptors In Vivo and In Vitro
Tchélingérian, J., Monge, M., Le Saux, F., Zalc, B., & Jacque, C. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65052377.x · Cited by 61
Martin, D., Near, S. L., Bendele, A. M., & Russell, D. A. (1995) · Experimental Neurology · doi:10.1016/0014-4886(95)90044-6 · Cited by 61
The role of TRAIL/TRAIL receptors in central nervous system pathology
Aktaş, O., Schulze‐Topphoff, U., & Zipp, F. (2007) · Frontiers in bioscience · doi:10.2741/2281 · Cited by 60
Ryan, L. A., Peng, H., Erichsen, D. A., Huang, Y., Persidsky, Y., Zhou, Y., Gendelman, H. E., & Zheng, J. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2003.11.019 · Cited by 59
The therapeutic effect of TNFR1-selective antagonistic mutant TNF-α in murine hepatitis models
Shibata, H., Yoshioka, Y., Ohkawa, A., Abe, Y., Nomura, T., Mukai, Y., Nakagawa, S., Taniai, M., Ohta, T., Mayumi, T., et al. (2008) · Cytokine · doi:10.1016/j.cyto.2008.07.003 · Cited by 56
Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer’s disease
Tansey, M., & McAlpine (2008) · Journal of Inflammation Research · doi:10.2147/jir.s4397 · Cited by 54
Minden, K., Aganna, E., McDermott, M. F., & Zink, A. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.016006 · Cited by 53
Ependymal cells of the choroid plexus express tumour necrosis factor‐α1
Tarlow, M. J., Jenkins, R., Comis, S. D., Osborne, M. P., Stephensl, S., Stanley, P., & Crocker, J. (1993) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1993.tb00447.x · Cited by 52
Allenbach, C., Launois, P., Mueller, C., & Tacchini‐Cottier, F. (2008) · European Journal of Immunology · doi:10.1002/eji.200737662 · Cited by 48
Kyrargyri, V., Vega‐Flores, G., Gruart, A., Delgado-Garcia, J. M., & Probert, L. (2014) · Glia · doi:10.1002/glia.22756 · Cited by 47
Self-citationTumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease
Leng, A., Mura, A., Feldon, J., & Ferger, B. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.10.077 · Cited by 46
Uberti, D. L., Ferrari‐Toninelli, G., Bonini, S. A., Sarnico, I., Benarese, M., Pizzi, M., Benussi, L., Ghidoni, R., Binetti, G. G., Spano, P., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301185 · Cited by 45
Kontermann, R. E., Münkel, S., Neumeyer, J., Müller, D., Branschädel, M., Scheurich, P., & Pfizenmaier, K. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31816a88f9 · Cited by 43
Upregulation of NF-κB-Dependent Gene Expression Mediated by the p75 Tumor Necrosis Factor Receptor
RAO, P., Hsu, K. C., & Chao, M. V. (1995) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1995.15.171 · Cited by 42
Antagonists of TNF action: clinical experience and new developments
Kontermann, R. E., Scheurich, P., & Pfizenmaier, K. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440902785167 · Cited by 42
Emmanouil, M., Taoufik, E., Tseveleki, V., Vamvakas, S.-S., Tselios, T., Karin, M., Lassmann, H., & Probert, L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900834 · Cited by 39
Self-citationWheeler, R. D., Zehntner, S. P., Kelly, L. M., Bourbonnière, L., & Owens, T. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02395.x · Cited by 36
Musicki, K., Briscoe, H., Tran, S., Britton, W. J., & Saunders, B. M. (2006) · Infection and Immunity · doi:10.1128/iai.02004-05 · Cited by 28
Cited by
Jang, D.-I., Lee, A.-H., Shin, H.-Y., Song, H.-R., Park, J.-H., Kang, T.-B., Lee, S.-R., & Yang, S.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052719 · Cited by 1,694
TNF biology, pathogenic mechanisms and emerging therapeutic strategies
Kalliolias, G. D., & Ivashkiv, L. B. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.169 · Cited by 1,387
Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases
Yuan, J., Amin, P., & Ofengeim, D. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0093-1 · Cited by 967
Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution
Mathys, H., Adaikkan, C., Gao, F., Young, J. Z., Manet, E., Hemberg, M., De Jager, P. L., Ransohoff, R. M., Regev, A., & Tsai, L.-H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.039 · Cited by 740
Hellenbrand, D. J., Quinn, C. M., Piper, Z. J., Morehouse, C. N., Fixel, J. A., & Hanna, A. S. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02337-2 · Cited by 635
Metadata
- Authors
- Probert, L.
- Venue
- Neuroscience
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 302
- Pages
- 2-22
- ISSN
- 0306-4522 (ISSN-L)
- OpenAlex
- W823098362
- Cited by
- 495
- References
- 221
- FWCI
- 16.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.